948
Participants
Start Date
January 31, 2022
Primary Completion Date
August 18, 2022
Study Completion Date
February 9, 2023
Part1:Recombinant two-component COVID-19 vaccine (CHO cell)
2 doses. Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administration: Intramuscular (IM) injection
Part1: Placebo
2 doses. Before reconstitution: Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: Not Applicable; Does Volume: 0.5ml/dose; Routine of administration: IM injection;
Part2: Recombinant two-component COVID-19 vaccine (CHO cell)
1 dose.Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administrati
Part2: COVID-19 Vaccine, mRNA
1 dose. Intramuscular injection, 30 μg/0.3 mL.
The Health Centrum, Roxas City
Jiangsu Rec-Biotechnology Co., Ltd.
INDUSTRY